We present here the identification and characterization of Leishmania sterol 24-c-methyltransferase (SMT), as well as data on protection of mice immunized with this Ag formulated in MPL ® -SE. Serological evaluation revealed that SMT is recognized by VL patients. C57BL/6 mice immunized with this vaccine candidate plus MPL ® -SE showed Ag-specific Th1 immune responses characterized by robust production of IFN-␥ upon specific Ag re-exposure in vitro. Upon challenge with L. infantum, mice immunized with SMT plus MPL ® -SE showed significant lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone. The results indicate that SMT/MPL ® -SE can be an effective vaccine candidate for use against VL.
Introduction
Human leishmaniasis is a spectrum of diseases caused by protozoan parasites of the genus Leishmania. Leishmaniases are roughly classified into three types of diseases, cutaneous leishmaniasis (CL), mucosal leishmaniasis (ML) and visceral leishmaniasis (VL) according to the clinical manifestations. Visceral leishmaniasis, generally caused by species of the L. donovani complex, i.e. L. donovani and L. infantum (chagasi), is the most severe form, with approximately 500,000 new cases reported annually (information from World Health Organization: www.who.int/leishmaniasis/en/). Active VL is characterized by hematological and hepatosplenic abnormalities, and is generally fatal unless properly treated.
The parasites are transmitted by the bite of sandflies and the infecting promastigotes differentiate into and replicate as amastigotes within macrophages in the mammalian host. In common with other intracellular pathogens, cellular immune responses are critical for protection against leishmaniasis. Th1 immune responses play an important role in mediat-ing protection against Leishmania, including roles for CD4 + and CD8 + T cells, IFN-␥, IL-12, TNF-␣ and NO, whereas inhibitory effects have been reported for IL-10 and TGF-␤ [1] [2] [3] [4] [5] [6] [7] [8] [9] . Effective immunization against leishmaniasis in animal models can be effected by delivery of Ag-encoding DNA vectors [10] [11] [12] or by administration of proteins formulated with Th1-inducing adjuvants including IL-12 [13] [14] [15] or TLR ligands such as CpG oligonucleotides [16] [17] [18] and monophosphoryl lipid A [19, 20] .
There has been significant progress in the development of safe and effective adjuvants for T cell mediated vaccines. There is also progress in characterization of defined antigens protective against VL in animal models as sub-unit or DNA vaccines such as KMP11, HASPB, A2 and CPB [21] [22] [23] [24] [25] [26] [27] , whereas there are still only a limited number of bona fide vaccine candidates to combat this disease and no vaccine is available for human use yet. We have recently identified a number of L. infantum Ags by serological screening using sera from L. infantum-infected hamsters [28] . Sterol 24-cmethyltransferase (SMT), one of the identified Ags, is an enzyme involved in biosynthesis of ergosterol, which is a target molecule of leishmanicidal and fungicidal amphotericin B [29] . Amphotericin B shows selective killing activity against some protozoan parasites and fungi, as ergosterol is not found in mammalian cells. Similarly, SMT is found in several parasites, fungi and plants, but is absent in mammals.
In this study, we produced recombinant SMT and tested its antigenicity, immunogenicity and protective efficacy. Because BALB/c and C57BL/6 mice show similar kinetics in parasite burden during L. infantum infection [30] , we used C57BL/6 mice for evaluating protective efficacy of SMT formulated in MPL ® -SE against L. infantum infection in this study, as performed in our previous study to evaluate the Leish-111f vaccine [31] .
Materials and methods

Animals and parasites
Female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA), and were maintained in specific-pathogen-free conditions. Eight-to twelve-week-old mice at the beginning of experiments were used. Promastigotes of L. infantum (MHOM/BR/82/BA-2) were cultured in MEM (Invitrogen, Carlsbad, CA) supplemented with 0.5× MEM essential amino acids solution (Invitrogen), 0.1 mM MEM non-essential amino acids (Invitrogen), 1 mM sodium pyruvate, 25 mM HEPES, 8.3 mM glucose, 26 mM sodium bicarbonate, 1 g/ml para amino benzoic acid, 50 g/ml gentamicin 10% heat-inactivated fetal bovine serum and 6 g/ml hemin. Promastigotes of L. donovani and L. major (MHOM/IL/80/Friedlin) were kindly provided from Dr. David Sacks, National Institutes of Health, and cultured in Medium 199 as previously described [32] . Promastigotes in a late log or stationary phase were used for infections or Ag preparations.
Cloning of L. infantum SMT and production of the recombinant protein
An open reading frame of L. infantum SMT was amplified by PCR using L. infantum genomic DNA with a set of primers, 5 CAA TTA CAT ATG TCC GCC GGT GGC CGT G, 3 CAA TTA AAG CTT CTA AGC CTG CTT GGA CGG. The amplified PCR product was inserted inframe with a 6xHis tag into the NdeI/HindIII site of the vector pET-28a (EMD Biosciences, San Diego, CA) and the insert was sequenced. The deduced amino acid sequence of L. infantum SMT was compared with those of SMTs from L. donovani (accession no. AAR92098), L. major (CAJ09196), Trypanosoma cruzi (EAN81270) and Candida albicans (AAC26626), which were obtained from the NCBI database (www.ncbi.nlm.nih.gov/), using the MegAlign software package (DNASTAR Inc., Madison, WI) by the Clustal method.
The pET-28a vector cloned for L. infantum SMT was transformed into E. coli Rosetta. The transformed E. coli was cultured in 2× YT medium and expression of the recombinant protein was induced by cultivation with 1 M isopropyl-␤-d-thiogalactoside for 3 h. Inclusion body was formed after lysing cells by sonication and centrifuging at 10,000 × g. The inclusion body was washed with 1% CHAPS and then resolubilized in 8 M urea. rSMT was then purified as 6xHis-tagged proteins using Ni-NTA agarose (Qiagen Inc., Valencia, CA), by binding protein to the agarose, washing the agarose with sodium deoxycolate and eluting protein with 400 M imidazole in 8 M urea. The eluted protein was dialyzed with 20 mM Tris (pH: 10) and concentration of the purified protein was measured by BCA protein assay (Pierce Biotechnology Inc., Rockford, IL). Purity of the proteins was assessed by Coomassie blue-staining following SDS-PAGE. An endotoxin level of the protein was measured by a Limulus amebocyte lysate test (Cambrex Corporation, East Rutherford, NJ) and shown to be below 10 EU/mg of protein.
Immunization of mice
Eight mice were immunized with 10 g of rSMT plus 20 g of MPL ® -SE (GlaxoSmithKline Biologicals, Rixensant, Belgium) in a volume of 0.1 ml. Another group of mice was administrated with 10 g of rSMT alone. Control groups received either saline or MPL ® -SE alone. The mice were immunized subcutaneously three times at three weeks intervals in the right hind footpad and at the base of the tail.
Western blotting
Samples for immunoblotting were prepared by suspending promastigotes in SDS sample buffer followed by boiling for 5 min. Samples containing 5 × 10 5 promastigotes were separated by SDS-PAGE and blotted on polyvinylidene difluoride membranes. Polyclonal Ab obtained from mice immunized three times with 10 g of rSMT plus 20 g of MPL ® -SE were used for western blotting. Sera from naïve mice were used at the same dilution as a control. The membranes were then probed with HRP-conjugated goat anti-mouse IgG. (Rockland Immunochemicals, Inc., Gilbertsville, PA). Development was performed using Chemiluminescent Super Sensitive HRP Substrate Kit (BioFX Laboratories, Owings Mills, MD).
ELISA for human anti-SMT IgG
rSMT was diluted in ELISA coating buffer, and 96-well plates were coated with 200 ng/well of Ag followed by blocking with phosphate-buffered saline containing 0.05% Tween-20 and 1% bovine serum albumin. Next, the plates were incubated with Brazilian VL patient sera (n = 21) as well as sera from Chagas disease patients (n = 10), endemic healthy donors (n = 10) and non-endemic healthy donors (n = 6) at 1:200 dilution. For total IgG, HRP-conjugated antihuman IgG (Rockland Immunochemicals) was used at the concentration of 200 ng/ml as the secondary Ab. For IgG subclass assay, HRP-conjugated anti-human IgG1, IgG2, IgG3 or IgG4 (Invitrogen) at 1/2000 dilution were used. The plates were developed with tetramethylbenzidine peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) and read by a microplate reader at 450 nm (570 nm reference).
ELISA for mouse anti-SMT IgG
The ELISA protocol was similar to that described above but different primary and secondary antibodies were used. Three mice per group were bled one week after the last immunization for Ab ELISA. Mouse serum samples were diluted to 1:100 and applied to the plates in 5-fold serial dilutions. Then the plates were incubated with HRP-conjugated goat anti-mouse IgG1 or IgG2a (Southern Biotech, Birmingham, AL). The plates were developed with the substrate and read by a microplate reader at a 450 nm wavelength.
Cytokine assay using spleen cells
Spleens were collected from three mice per group two weeks after the last immunization. 2 × 10 5 splenocytes in complete RPMI medium (RPMI supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml of penicillin and 100 g/ml of streptomycin) per well were plated in a 96-well plate and then stimulated with 3 g/ml of con A, 100 g/ml of L. infantum soluble lysate Ag (LiSLA), 10 g/ml of rSMT or medium alone. Culture supernatants were collected after 72 h cultivation and tested the levels of IFN-␥ and IL-10 by sandwich ELISA.
Intracellular staining and Flowcytometry
Spleens were collected from three mice per group two weeks after the last immunization. 1 × 10 6 splenocytes in 100 l of complete RPMI per well were plated in a round bottom 96-well plate and then stimulated with PMA/ionomycin, 10 g/ml of rSMT or medium alone. Co-stimulation antibodies anti-CD28 (eBioscience, San Diego, CA) and anti-CD49d (eBioscience) were added to the media for a final concentration of 1 g/ml in the well during stimulation. After 2 h incubation at 37 • C, brefeldin A (GolgiPlug: BD Biosciences, San Jose, CA) was added to the wells and the incubation resumed for an additional 12 h at 37 • C. Cells were blocked with anti-CD16/32 (eBioscience) 1:50 in 50 l and then stained with AlexaFluor 700-anti-CD3 (eBioscience), PerCP-anti-CD4 (BD Biosciences), PE-anti-CD8 (BD Biosciences). Then cells were fixed using the Cytofix/Cytoperm kit (BD Biosciences). Cells were again blocked with anti-CD16/32 and then intracellularly stained with FITC-anti-TNF-␣ (eBioscience), Pacific Blue-anti-IL-2 (eBioscience) and PE-Cy7-anti-IFN-␥ (BD Biosciences). Cells were analyzed with a LSRII FACS machine (BD Biosciences) and the DIVA software.
Challenge of mice with L. infantum
Five mice per group were challenged with L. infantum three weeks after the last immunization. 5 × 10 6 L. infantum promastigotes were suspended in Hank's balanced salt solution and injected i.v. into the tail vein of the mouse. At four weeks after the challenge, mice were sacrificed to collect spleens and livers to determine the numbers of parasites in these tissues by limiting dilution assay. The tissues were homogenated with glass grinders and the suspensions were 2-fold serially diluted with complete HOMEM in 96-well microplates with NNN blood agar. Each well was examined the presence of parasites 10 days after plating, and the numbers of parasites in the original tissues were calculated based on dilution factor of the last positive well.
Results
SMT is expressed by Leishmania species
An open reading frame of SMT was cloned from L. infantum total DNA by PCR amplification using specific primers. The size was 1062 bp and the sequence was 100% matched with the one on the database (LinJ36.4930; 1062 bp, 353 amino acids, 39.8 kDa, obtained from GeneDB: www.genedb.org/). A sequence analysis using the NCBI database (www.ncbi.nlm.nih.gov/) revealed that L. infantum SMT has 99.6%, 96.6%, 66.0% and 38.5% identity to SMTs from L. donovani, L. major, T. cruzi and C. albicans, respectively (Fig. 1) .
rSMT was expressed in E. coli and purified (Fig. 2 ). An apparent molecular mass of the protein was as predicted (42 kDa: because of 20 aa extra His-tag streach on N-terminal). Mouse polyclonal Ab raised against rSMT was used for detection of native SMT in Leishmania species by western blot analysis. Anti-SMT Ab detected a band with apparent molecular sizes of 38 kDa, which is in a same range of the predicted size, in all the Leishmania species tested, i.e. L. donovani, L. infantum and L. major, whereas the intensity of the bands was different (Fig. 3) . Those bands were not detected when sera from naïve mice were used as the primary Ab.
VL patient sera recognize rSMT
To determine antigenicity of Leishmania SMT in humans, examined the prevalence of antibodies to rSMT and rK39 in VL patients by ELISA using sera from 21 Brazilian VL patients. rK39 is a serodiagnostic Ag and the presence of antibodies to the Ag indicates active VL [33] . Nineteen of the 21 showed strong Ab responses to rK39 and those responses were specific in VL patients (Fig. 4A) . Those sera showed moderate to strong reactivity to rSMT, and these Ab responses seemed to be specific in VL patients, whereas one nonendemic healthy donor showed moderate response (Fig. 4B) . rSMT was recognized by Sudanese VL patients infected with L. donovani (data not shown), suggesting that SMT is antigenic in both L. donovani-and L. infantum-infected patients.
The sera were further examined to determine their IgG subclasses. IgG1, IgG2 and IgG3 responses to rK39 were detected in VL patient sera and IgG1 was the predominant subclass (Fig. 4C) . IgG1 response was predominant to rSMT as well, despite the titers were lower than those to rK39 (Fig. 4D) . Some IgG2 responses were observed in VL patient sera to rSMT, but that was not VL-specific, as health donors showed IgG2 response to this Ag. Little IgG4 responses were detected to either rK39 or rSMT.
rSMT plus MPL ® -SE induce immune responses with Th1 characteristics
Since the rSMT plus MPL ® -SE vaccine induced protection against VL in mice, we then evaluated immune responses induced by the vaccine. Mice immunized with rSMT plus MPL ® -SE showed robust humoral responses to rSMT characterized by high levels of Ag-specific IgG1 and IgG2a (Fig. 5) . In contrast, immunization with rSMT alone resulted in IgG1-dominant Ab responses. Mice injected with saline or adjuvant alone showed no Ab responses to rSMT.
To investigate cell-mediated responses brought about by the immunization, cytokine production by spleen cells in stimulation with rSMT or LiSLA were measured. Spleen cells from mice immunized with rSMT plus MPL ® -SE produced a high level of IFN-␥ in response to rSMT (Fig. 6A) . These mice also responded to LiSLA stimulation; albeit the magnitude of IFN-␥ production was much lower than that observed with rSMT stimulation. In contrast, spleen cells from mice immunized with rSMT alone produced only a low level of IFN-␥ in response to rSMT. Compared with SMT alone, SMT plus MPL-SE induced 30 times higher IFN-␥ response, whereas IL-10 level was only twice higher, suggesting that MPL-SE skews immune responses to vaccine antigens toward Th1 (Fig. 6B) . No detectable cytokine production was found in saline or adjuvant alone groups in stimulation with rSMT or LiSLA.
rSMT plus MPL ® -SE induce both CD4 + and CD8 + cells expressing multiple Th1-type cytokines
To further investigate cellular responses induced by rSMT plus MPL ® -SE vaccination, flowcytometric analysis of Th1- type cytokine production by CD4 + and CD8 + T-cells was performed. Spleen cells, which were harvested after in vitro cultivation with or without SMT, were gated based on forward and side scatter first, then CD3 expression (Fig. 7A) . CD4 + or CD8 + cells were further gated from the CD3 + population. Those populations were analyzed the frequency of cells producing TNF-␣, IL-2 or IFN-␥.
FACS data show that Ag-specific CD4 + and CD8 + cells were induced by rSMT plus MPL ® -SE vaccination (Fig. 7B) . CD4 + cells producing TNF-␣, IL-2 or IFN-␥ in stimulation with rSMT were found only in that group of mice. Ag-specific CD8 + cells were also found in mice administrated rSMT plus MPL ® -SE, and those cells were found producing TNF-␣ and IFN-␥.
When CD4 + and CD8 + cells were further divided into seven distinct populations based on expression patterns of TNF-␣, IL-2 or IFN-␥ at a single-cell level, it was revealed that many of Ag-specific T-cells producing multiple cytokines were induced by rSMT plus MPL ® -SE (Fig. 7C ). There were both CD4 + and CD8 + cells producing only TNF-␣ in stimulation with rSMT, whereas cells expressing only IFN-␥ were little. Most of Ag-specific CD4 + T-cells producing IFN-␥ were co-expressing TNF-␣ or both TNF-␣ and IL-2. Also, many of the Ag-specific CD8 + T-cells were producing both TNF-␣ and IFN-␥.
rSMT-vaccinated mice are resistant against L. infantum infection
To evaluate the protective efficacy of rSMT plus MPL ® -SE vaccination against VL, immunized mice were challenged by intravenous injection of 5 × 10 6 L. infantum promastigotes. During L. infantum infection, C57BL/6 mice showed peak parasite burden at four weeks of infection in the liver and between four and eight weeks in the spleen (data not shown). Thus, we chose four weeks as a time point for determining parasite numbers in spleens and livers of challenged mice. Significant reduction of parasites was seen in mice immunized with rSMT plus MPL ® -SE compared with those in saline or adjuvant alone groups (Fig. 8) . The immunized mice showed 43-fold and 55-fold reduction in the number of parasites in spleens, 111-fold and 117-fold reduction in livers compared with saline and adjuvant alone groups, respectively. There was no significant difference observed between saline and adjuvant alone groups. This protection in SMT-immunized mice was repeatedly observed with similar magnitude.
Discussion
There have been a limited number of vaccine candidates which have been shown to induce protection against VL in animal models [21] [22] [23] 27] . In this study, we demonstrated that immunization with L. infantum SMT plus MPL ® -SE induced a mixture of Th1 and Th2 responses to the vaccine antigen and significantly protected mice from L. infantum, a causative agent of VL in humans and dogs.
Protection derived from the L. infantum SMT plus MPL ® -SE vaccine seems to be associated with Ag-specific Th1 immune responses. And this effective protection was most likely affected by the combination of Ag and adjuvant. In previous studies, we have shown that MPL ® -SE contributes as a Th1-inducing adjuvant to protection against CL when formulated with a recombinant fusion protein, Leish-111f [19, 20] . In this study, we showed the induction of both Agspecific CD4 + and CD8 + T-cells by the rSMT plus MPL ® -SE vaccine. Also, we demonstrated that the rSMT plus MPL ® -SE vaccine induced Ag-specific T-cells which are capable of producing multiple Th1-type cytokines in response to Ag recall. All of TNF-␣, IL-2 and IFN-␥ are involved in protection against VL [4, 5, 34] . As TNF-␣ synergizes with IFN-␥ in killing Leishmania parasites [35] , induction of Agspecific T-cells capable of producing multiple cytokines upon Ag recall might be more beneficial for control of Leishmania infection than those producing single cytokine, and such induction may be a good indicator whether a vaccine composed of Ag and adjuvant is protective against leishmaniasis.
Because Th1 immune responses play an important role in controlling leishmaniasis, T-cell Ags have been thought to be good vaccine targets. We have attempted to identify such Ags through T-cell screening or MHC class II screening [36, 37] , however, none of them were protective against VL. In contrast, SMT was identified by serological screening of an expression library using VL patient sera [28] . Interestingly, most of the known vaccine Ags including HASPB1 (K26), A2 and KMP-11 are also known as serological Ags which detect antibodies in sera of VL patients [38, 39] . Although the significance of Ag-specific IgG subclasses in humans is not fully understood yet, there are associations between IgG subclasses and cytokine profiles. For example, IL-4 facilitates in switching of IgM-expressing B cells to the production of IgG4 [40] . IL-10 appears to represent a switch factor for IgG1 and IgG3 [41] , whereas IFN-␥ induces IgG2 production while suppressing the production of IgG1 [42] . Patients with active VL have a high prevalence of antibodies to leishmanial Ags while producing the regulatory cytokine IL-10 and lacking Th1 immune responses [43] [44] [45] . Therefore, IgG1-dominant response of VL patients to SMT is indicative of the involvement of the Ag in disease promotion during human VL. We are now examining cellular immune responses of asymptomatic or cured VL patients to SMT to examine whether or not this Ag is associated with protective immunity against VL.
We have demonstrated that SMT is expressed by both L. infantum and L. donovani, the two causative agents of VL, as well as L. major causing CL in the Old World. This SMT expression pattern suggests that the Ag may also be useful in other forms of leishmaniasis. Furthermore, the lack of homology with mammalian proteins may give SMT safety advantages. SMT is also found in other pathogens including parasites and fungi such as Trypanosoma spp. [46] , Candida albicans [47] and Pneumocystis carinii [48] . Although the functional role of SMT in ergosterol biosynthesis is well studied, its antigenicity during such infections has not been unknown. Thus, it is of interest to evaluate whether SMT is involved in or can be a vaccine Ag against infections other than VL.
